Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Biomedtracker: see the drug development process through analysts’ eyes

Real-time tracking and analysis of the drug development pipeline

Key benefits:

Market Events & Catalysts
Likelihood of Approval
Deals Coverage

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

View all content

Biomedtracker, Datamonitor Healthcare

Key Potential Drug Launches in 2021

Valuable insight and expert analyst commentary 2021’s expected drug launches, their indications, commercial potential, regulatory catalysts and more.

View article
In Vivo, Scrip

BIO-Europe Biopharma Deals and Financing eBook

2020 coverage from Scrip and In Vivo provides rich insights into the attitudes and trends around deals and financing, two major engines of innovation and growth for biopharma during this current pandemic period.

View article
Scrip

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.

Topic Coronavirus Manufacturing Clinical Trials

View article
Scrip

First COVID-19 Trial Success For Roche's Actemra, But No Sign It Saves Lives

A composite endpoint conceals Actemra’s lack of mortality benefit – while life-saving dexamethasone gets EMA endorsement.

Topic Coronavirus

View article
Scrip

Dr Reddy's To Steer Russian COVID-19 Vaccine Plans In India

Dr Reddy’s combines forces with the Russian Direct Investment Fund for clinical trials and supply of Sputnik V in India, amid what it views as “very important” data points in early studies of the COVID-19 vaccine.

Topic Coronavirus Vaccines

View article
Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Topic Coronavirus Clinical Trials Vaccines

Full podcast
Scrip

Lilly's Olumiant Cuts COVID-19 Hospital Stays By One Day

Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.

Topic Coronavirus Clinical Trials Research & Development

View article
Scrip

Silver Linings: COVID-19 Creates Investment Bubble, Golden R&D Era

A choice asset in the middle of a pandemic, pharma companies could see the investment bubble burst once normalcy is on the horizon. But interest will continue in innovators, rather than big pharma specifically, predicts an expert panel featuring Biogen's chairman, a former Sanofi CEO and an ex-NIH director

Topic Coronavirus Research & Development

View article
In Vivo, Medtech Insight, Pink Sheet, Scrip

The Rise of Digital Tools eBook

Explore how digital technologies are being used to address the disruption of clinical trials for drugs and medical technology caused by COVID-19. Stay current with insights from industry leaders, information on guidance and regulation, and an examination of how the challenges of this global crisis and the industry’s response to it may soon usher in a new era in worldwide healthcare.

Topic Coronavirus

View article
HBW Insight, Generics Bulletin, Medtech Insight, Datamonitor...

Pharma Intelligence Launches Alexa Skill

Keep up with topics you care about in Pharma and Medtech with the new Alexa Skill from Informa Pharma Intelligence. Now you can listen to our podcasts on subjects you choose, right from your Alexa smartphone app!

Topic Artificial Intelligence Consumer Innovation

View article
Scrip

Pharma Stands Up To Trump Pressure With COVID-19 Vaccines Science Pledge

CEOs from the most advanced vaccines developers pledge to maintain standards – for the sake of safety, efficacy and public trust in vaccines

Topic Clinical Trials

View article
Scrip

AstraZeneca's COVID Vaccine On Hold: A Reminder Drug Development Is Never Straightforward

The company – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.

Topic Coronavirus Vaccines

View article
Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Topic Cell & Gene Therapy

Full podcast
Scrip

Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To 'Follow Science' In Vaccine Trials

The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.

Topic Coronavirus Clinical Trials Research & Development

View article
Scrip

Coronavirus Update: End Of The Road For Kevzara In COVID-19

Sanofi/Regeneron are ending development of Kevzara for COVID-19 after Phase III disappointments. Meanwhile Regeneron is ramping up biologics manufacturing in Ireland as it makes way for COVID-19 antibody production in New York, and multiple vaccines move forward in Japan with new funding and trials

Topic Coronavirus Clinical Trials

View article